2011-09-19
Affibody appoints Dr. Fredrik Frejd as VP Research
Stockholm, September 19, 2011
Affibody AB announced today that Ass. Prof. Fredrik Frejd has been appointed to VP Research. Dr. Frejd has worked at Affibody AB since 2002, most recently as Director Discovery.
Dr. Frejd has over fifteen years of experience in life science research with particular expertise in tumor biology, phage display and therapeutic protein engineering of antibody fragments and alternative scaffolds. In his position as Vice Preseident Research, Dr. Frejd will be closely involved in the development and management of Affibody’s therapeutic programmes. He will report to David Bejker, CEO.
Dr. Frejd joined Affibody AB as project manager in 2002 and has since been instrumental in developing the therapeutics program within the company. In 2010 he was appointed Director Discovery at the company, overseeing the internal research portfolio. Dr Frejd is affiliated with the unit for Biomedical radiation sciences, Uppsala University, as associate professor.
Dr. Frejd received his Ph.D. in Molecular Biology from the Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland, working on therapeutic targeting of tumoral angiogenesis.